In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector for part 2 of our conversation with Thomas Eldered, Executive Chairman at Flerie. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering: The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies Flerie’s mission and its patient-centric investment strategy in life sciences. The story behind Thomas’ signature bowtie look… Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.